Assuta Rise

Assuta Rise is the innovation arm of Assuta Medical Center, structured as an accelerator with explicit programs run alongside AWS and Nvidia. The combination is unusual, and it reflects a specific bet on AI radiology, diagnostics, and clinical AI as the categories where Israeli founders are most positioned to compete in US markets.

The thesis is direct. Diagnostic AI and clinical decision-support tools require real clinical environments for validation, real cloud and compute partnerships for deployment at scale, and real US market access for commercial relevance. Assuta Rise is structured to provide all three: clinical environment from Assuta, technical partnership with AWS and Nvidia, and commercial preparation for US expansion. Portfolio activity concentrates on digital health and AI/ML in healthcare, with particular emphasis on radiology, imaging, diagnostic AI, and the broader category of AI-driven clinical software.

Checks fall below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, structured as part of accelerator programs rather than standalone investments. Geography is anchored in Israeli founders, almost always with explicit US market focus. The program is unusual in how seriously it treats US expansion as a structural part of company building, with the AWS and Nvidia partnerships providing technical infrastructure and the program’s curriculum oriented toward navigating US clinical buyers. Assuta Rise is positioned as a stepping stone for technically credible clinical AI startups that need both clinical validation and commercial readiness before raising institutional capital.

The team operates with the cadence of a structured accelerator program. Founders engage directly with clinical staff at Assuta, with technical partners at AWS and Nvidia, and with operating staff focused on US commercial preparation. The diligence engages with clinical validation, regulatory pathway, and the commercial realities of selling AI products into US health systems and imaging centers. The bias is toward founders building products with real clinical defensibility rather than narrative-driven AI plays.

In practice, the value-add concentrates where Israeli AI healthcare founders most often struggle: clinical validation in environments that look like the eventual deployment context, technical partnership at the cloud and inference layer, and the translation from a clinically promising prototype to a product that US health systems will buy. Assuta Rise is direct about scope. It is not a generalist healthcare investor, it is not focused on therapeutics or hardware-heavy devices, and it is not a follow-on capital partner at scale. For founders building AI radiology, diagnostic AI, or clinical decision-support products with real US ambitions, Assuta Rise is one of the more substantive clinical-origin programs in Israel. The conversations are clinically grounded, the technical partnerships are real, and the founders who do well here treat the program as a structured runway to commercial readiness rather than as a credentialing exercise.